Minoryx Therapeutics

Minoryx is a clinical stage biotech company developing new therapies for orphan CNS diseases with a high unmet medical need. The company’s lead program leriglitazone (MIN-102) is in a phase 2/3 clinical trial for the treatment of adrenomyeloneuropathy, the most common phenotype of X-linked Adrenoleukodystrophy, and in a phase II study in Friedreich’s Ataxia
Minoryx portfolio Ysios Capital

Minoryx therapeutics
TecnoCampus Mataró-Maresme
Av. Ernest Lluch 32, TCM3
Mataró, 08302